SynapCell
Entity

  • SynapCell

    Created in 2005
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    218 3,784

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    SMB

  • Location

    Chem. des Prêles, 38330 Saint-Ismier, France

    Saint-Ismier

    France

  • Employees

    Scale: 11-50

    Estimated: 40

  • SIREN

    481563526

  • Engaged corporates

    11
    5 7

  • Added in Motherbase

    4 years, 9 months ago
Description
  • Value proposition

    We identify your most effective drug candidates in vivo with objective and translational measures within the brain. #EEG

    SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as schizophrenia.
    Since 2005, our returning customers in USA, Japan, Korea or Europe helped the company establish a unique reputation on the market and is the basis for long-lasting successful business partnerships.


    Drug discovery solutions, Central Nervous System, Integrated electrophysiology, EEG biomarkers, Rodent models, Translational, brain, Innovation & services, Predictive Biomarkers, CRO, Contract Research Organization, pharmaco-EEG, Epilepsy, Parkinson, Pharmaco-resistant epilepsy, MTLE, GAERS, AERP, Biomarker, Tremor, neural network, oscillations, and Preclinical CNS CRO

  • Original language

    We identify your most effective drug candidates in vivo with objective and translational measures within the brain. #EEG

    SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as schizophrenia.
    Since 2005, our returning customers in USA, Japan, Korea or Europe helped the company establish a unique reputation on the market and is the basis for long-lasting successful business partnerships.

  • Preclinical EEG CRO for CNS drug discovery | SynapCell

    Partner with SynapCell, the leading CRO in preclinical EEG for CNS drug discovery. Specialized in epilepsy, psychiatric, and rare disorders.

    • https://synapcell.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Région Auvergne-Rhône-Alpes
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration 		Not capitalistic
Partnership
Event

18 Sep 2020


Similar entities
Last news
Show all articles
Social network dynamics